. Photo via Getty Images

CruxOCM, a startup with a significant Houston presence that specializes in robotic industrial process automation for energy companies, has secured even more business from energy giant Phillips 66.

The value of the deal wasn’t disclosed.

Houston-based Phillips 66 has agreed to expand it use of CruxOCM’s pipeBOT technology to cover even more pipelines. The pipeBOT technology is designed to improve the safety and efficiency of control room operations for pipelines and reduce control room costs.

CruxOCM and Phillips 66 launched a test of pipeBOT in 2020.

CruxOCM, based in Calgary, Canada, says pipeBOT is engineered to decrease manual controls through intelligent automation. With this technology in place, the fatigue of control room operators declines, because as many as 85 percent fewer manual commands must be entered, according to CruxOCM. Therefore, control room operators can focus on higher-level tasks.

“At CruxOCM, we empower control room operators with modern software that enables the autonomous control rooms of tomorrow, within the safety constraints of today. We look forward to continuing to strengthen our relationship with Phillips 66 for many years to come,” Adam Marsden, chief revenue officer at CruxOCM, says in a news release.

Founded in 2017, Crux OCM (Crux Operations Control Management) established its Houston presence last year. Also in 2021, the startup raised $6 million in venture capital in a “seed extension” funding round. Bullpen Capital led the round, with participation from Angular Ventures, Root Ventures, Golden Ventures, Cendana Capital, and Industry Ventures.

In 2019, Angular Ventures and Root Ventures co-led a $2.6 million funding round.

A Canadian software company with operations in Houston raised fresh funding. Photo via Getty Images

Energy software company with Houston presence snags $6M in funding

money moves

CruxOCM, a Canadian tech startup that is establishing a Houston outpost, has collected $6 million in venture capital.

Bullpen Capital led the "seed extension" funding round, with participation from Angular Ventures, Root Ventures, Golden Ventures, Cendana Capital, and Industry Ventures. In 2019, two years after CruxCOM was founded, Angular Ventures and Root Ventures co-led a $2.6 million funding round.

Calgary-based CruxOCM, says the new capital will go toward expanding its product lines, boosting the efficiency of its installation process, and growing its North American team. The company plans to extend its product reach to operators of gas plants, gas pipelines, and offshore facilities.

The startup makes software for control rooms operated by energy companies.

"Control rooms are the brains, heart, and soul of the energy sector, and they are in dire need of innovation. Our mission to give control room operators superpowers will ensure the efficiency and safety of an essential infrastructure we rely on daily," Vicki Knott, co-founder and CEO of CruxOCM, says in a September 14 news release.

Knott is a chemical engineer and former control room operator.

The company's robotic industrial process automation (RIPA) serves as the foundation for CruxOCM's gatherBOT and pipeBOT automation products. The introduction of two more products — powerOPT and draOPT — is underway. Houston-based Phillips 66 is piloting the powerOPT technology.

CruxOCM works with companies that have market capitalizations of $17 billion to $77 billion to improve control room efficiency and safety through automation.

"CruxOCM's RIPA is a game-changer in the industry, and we're thrilled to be a part of this next growth stage," says Eric Wiesen, managing partner of Bullpen Capital. "RIPA is crucial for bringing increased efficiency into existing heavy-industry control room infrastructure while maintaining safety. Even as we prioritize green energy initiatives globally, oil and gas will still be instrumental in the energy transition, so we must use technology to automate where we can while helping companies to augment metrics in order to hit ESG goals."

Knott recently told InnovationMap that CruxOCM has three full-time employees in Houston and is on track to add more workers in sales, product development, and engineering.

The CEO continues to hunt for office space in North Houston. "Depending on the comfort level of employees, it could be open in the next few months," a company spokeswoman says.

Today, CruxOCM employs 18 people, including the three workers in Houston, and aims to add six more employees by the end of 2021.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

5 Houston scientists named winners of prestigious Hill Prizes 2026

prized research

Five Houston scientists were recognized for their "high-risk, high-reward ideas and innovations" by Lyda Hill Philanthropies and the Texas Academy of Medicine, Engineering, Science and Technology (TAMEST).

The 2026 Hill Prizes provide seed funding to top Texas researchers. This year's prizes were given out in seven categories, including biological sciences, engineering, medicine, physical sciences, public health and technology, and the new artificial intelligence award.

Each recipient’s institution or organization will receive $500,000 in direct funding from Dallas-based Lyda Hill Philanthropies. The organization has also committed to giving at least $1 million in discretionary research funding on an ad hoc basis for highly-ranked applicants who were not selected as recipients.

“It is with great pride that I congratulate this year’s Hill Prizes recipients. Their pioneering spirit and unwavering dedication to innovation are addressing some of the most pressing challenges of our time – from climate resilience and energy sustainability to medical breakthroughs and the future of artificial intelligence,” Lyda Hill, founder of Lyda Hill Philanthropies, said in a news release.

The 2026 Houston-area recipients include:

Biological Sciences: Susan M. Rosenberg, Baylor College of Medicine

Rosenberg and her team are developing ways to fight antibiotic resistance. The team will use the funding to screen a 14,000-compound drug library to identify additional candidates, study their mechanisms and test their ability to boost antibiotic effectiveness in animal models. The goal is to move toward clinical trials, beginning with veterans suffering from recurrent infections.

Medicine: Dr. Raghu Kalluri, The University of Texas MD Anderson Cancer Center

Kalluri is developing eye drops to treat age-related macular degeneration (AMD), the leading cause of vision loss globally. Kalluri will use the funding to accelerate studies and support testing for additional ocular conditions. He was also named to the National Academy of Inventors’ newest class of fellows last month.

Engineering: Naomi J. Halas, Rice University

Co-recipeints: Peter J. A. Nordlander and Hossein Robatjazi, Rice University

Halas and her team are working to advance light-driven technologies for sustainable ammonia synthesis. The team says it will use the funding to improve light-driven catalysts for converting nitrogen into ammonia, refine prototype reactors for practical deployment and partner with industry collaborators to advance larger-scale applications. Halas and Nordlander are co-founders of Syzygy Plasmonics, and Robatjazi serves as vice president of research for the company.

The other Texas-based recipients include:

  • Artificial Intelligence: Kristen Grauman, The University of Texas at Austin
  • Physical Sciences: Karen L. Wooley, Texas A&M University; Co-Recipient: Matthew Stone, Teysha Technologies
  • Public Health: Dr. Elizabeth C. Matsui, The University of Texas at Austin and Baylor College of Medicine
  • Technology: Kurt W. Swogger, Molecular Rebar Design LLC; Co-recipients: Clive Bosnyak, Molecular Rebar Design, and August Krupp, MR Rubber Business and Molecular Rebar Design LLC

Recipients will be recognized Feb. 2 during the TAMEST 2026 Annual Conference in San Antonio. They were determined by a committee of TAMEST members and endorsed by a committee of Texas Nobel and Breakthrough Prize Laureates and approved by the TAMEST Board of Directors.

“On behalf of TAMEST, we are honored to celebrate the 2026 Hill Prizes recipients. These outstanding innovators exemplify the excellence and ambition of Texas science and research,” Ganesh Thakur, TAMEST president and a distinguished professor at the University of Houston, added in the release. “Thanks to the visionary support of Lyda Hill Philanthropies, the Hill Prizes not only recognize transformative work but provide the resources to move bold ideas from the lab to life-changing solutions. We are proud to support their journeys and spotlight Texas as a global hub for scientific leadership.”

Investment bank opens new Houston office focused on energy sector

Investment bank Cohen & Co. Capital Markets has opened a Houston office to serve as the hub of its energy advisory business and has tapped investment banking veteran Rahul Jasuja as the office’s leader.

Jasuja joined Cohen & Co. Capital Markets, a subsidiary of financial services company Cohen & Co., as managing director, and head of energy and energy transition investment banking. Cohen’s capital markets arm closed $44 billion worth of deals last year.

Jasuja previously worked at energy-focused Houston investment bank Mast Capital Advisors, where he was managing director of investment banking. Before Mast Capital, Jasuja was director of energy investment banking in the Houston office of Wells Fargo Securities.

“Meeting rising [energy] demand will require disciplined capital allocation across traditional energy, sustainable fuels, and firm, dispatchable solutions such as nuclear and geothermal,” Jasuja said in a news release. “Houston remains the center of gravity where capital, operating expertise, and execution come together to make that transition investable.”

The Houston office will focus on four energy verticals:

  • Energy systems such as nuclear and geothermal
  • Energy supply chains
  • Energy-transition fuel and technology
  • Traditional energy
“We are making a committed investment in Houston because we believe the infrastructure powering AI, defense, and energy transition — from nuclear to rare-earth technology — represents the next secular cycle of value creation,” Jerry Serowik, head of Cohen & Co. Capital Markets, added in the release.

---

This article originally appeared on EnergyCaptialHTX.com.

MD Anderson makes AI partnership to advance precision oncology

AI Oncology

Few experts will disagree that data-driven medicine is one of the most certain ways forward for our health. However, actually adopting it comes at a steep curve. But what if using the technology were democratized?

This is the question that SOPHiA GENETICS has been seeking to answer since 2011 with its universal AI platform, SOPHiA DDM. The cloud-native system analyzes and interprets complex health care data across technologies and institutions, allowing hospitals and clinicians to gain clinically actionable insights faster and at scale.

The University of Texas MD Anderson Cancer Center has just announced its official collaboration with SOPHiA GENETICS to accelerate breakthroughs in precision oncology. Together, they are developing a novel sequencing oncology test, as well as creating several programs targeted at the research and development of additional technology.

That technology will allow the hospital to develop new ways to chart the growth and changes of tumors in real time, pick the best clinical trials and medications for patients and make genomic testing more reliable. Shashikant Kulkarni, deputy division head for Molecular Pathology, and Dr. J. Bryan, assistant professor, will lead the collaboration on MD Anderson’s end.

“Cancer research has evolved rapidly, and we have more health data available than ever before. Our collaboration with SOPHiA GENETICS reflects how our lab is evolving and integrating advanced analytics and AI to better interpret complex molecular information,” Dr. Donna Hansel, division head of Pathology and Laboratory Medicine at MD Anderson, said in a press release. “This collaboration will expand our ability to translate high-dimensional data into insights that can meaningfully advance research and precision oncology.”

SOPHiA GENETICS is based in Switzerland and France, and has its U.S. offices in Boston.

“This collaboration with MD Anderson amplifies our shared ambition to push the boundaries of what is possible in cancer research,” Dr. Philippe Menu, chief product officer and chief medical officer at SOPHiA GENETICS, added in the release. “With SOPHiA DDM as a unifying analytical layer, we are enabling new discoveries, accelerating breakthroughs in precision oncology and, most importantly, enabling patients around the globe to benefit from these innovations by bringing leading technologies to all geographies quickly and at scale.”